Search company, investor...
Nevro company logo


Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Nevro

Nevro (NYSE: NVRO) is a global medical device company focused on providing products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Headquarters Location

1800 Bridge Pkwy

Redwood City, California, 94065,

United States


Missing: Nevro's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nevro's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Nevro

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Nevro in 1 CB Insights research brief, most recently on Aug 6, 2020.

Expert Collections containing Nevro

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nevro is included in 2 Expert Collections, including Diabetes.



1,903 items


Medical Devices

950 items - excludes those without working websites.

Nevro Patents

Nevro has filed 215 patents.

The 3 most popular patent topics include:

  • Neurophysiology
  • Neurotechnology
  • Neurological disorders
patents chart

Application Date

Grant Date


Related Topics




Diabetes, Electrical signal connectors, Insulin therapies, Nutrition, Blood tests


Application Date


Grant Date



Related Topics

Diabetes, Electrical signal connectors, Insulin therapies, Nutrition, Blood tests



Latest Nevro News

Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Feb 1, 2023

02/01/2023 | 07:01am EST Message : Wednesday, March 1, 2023 at 8:45 am Eastern Time REDWOOD CITY, Calif., Feb. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, and Rod MacLeod, Nevro's CFO, will participate in a fireside chat at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 8:45 am Eastern Time at Citigroup's Corporate Headquarters in New York, NY. A webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at . Internet Posting of Information Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at To learn more about Nevro, connect with us on  LinkedIn ,  Twitter ,  Facebook  and  Instagram . Investors and Media:

Nevro Frequently Asked Questions (FAQ)

  • When was Nevro founded?

    Nevro was founded in 2006.

  • Where is Nevro's headquarters?

    Nevro's headquarters is located at 1800 Bridge Pkwy, Redwood City.

  • What is Nevro's latest funding round?

    Nevro's latest funding round is IPO.

  • How much did Nevro raise?

    Nevro raised a total of $133.5M.

  • Who are the investors of Nevro?

    Investors of Nevro include Three Arch Partners, Mayo Clinic Ventures, Bay City Capital, MPM Capital, Accuitive Medical Ventures and 7 more.

  • Who are Nevro's competitors?

    Competitors of Nevro include Orchestra BioMed, SetPoint Medical, INBRAIN Neuroelectronics, Neuros Medical, Theranica, Stimdia Medical, Lungpacer Medical, Saluda Medical, Cardionomic, Rune Labs and 47 more.

Compare Nevro to Competitors

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops a bioelectronic medicine platform using a small implanted device that activates the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The company was founded in 2006 and is based in Santa Clarita, California.

Cala Health

Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.

Synapse Biomedical Logo
Synapse Biomedical

Synapse Biomedical (SBI) was founded to commercialize the NeuRx Diaphragm Pacing System (DPS) that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency.

Nuvaira Logo

Nuvaira is a privately held company headquartered in Minneapolis, MN. The company’s proprietary Nuvaira Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA, and is CE Mark approved.

Theranica Logo

Theranica is a medical device company that develops advanced neuromodulation devices for migraine and other idiopathic pain conditions. It provides an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in people aged 12 and older. The firm serves clients operating in the healthcare sector. It was founded in 2016 and is based in Netanya, Israel.

eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.